02511 HIGHTIDE-B
- 1.780
- -0.080-4.30%
HIGHTIDE-B News
Statistics of abnormal proportion of CITIC HK Stock Connect on August 6th.
Statistics on unusual proportion of SmartHK Connect | August 5, 2024
Junshengtai Pharmaceutical (02511) rose 11% in the afternoon, and plans to establish a production raw material operating entity base in Hebei Cangzhou.
Jingu finance news | Junshengtai Medicine (02511) surged in the afternoon, with a report of HKD 1.29, up 11.21%, and a turnover of HKD 29.3397 million as of press time. On the news side, the company previously announced that, after negotiating with relevant local government departments, the group decided to establish a production raw material operation main base in Nan Dagang Industrial Park, Bohai New Area, Cangzhou City, Hebei Province, hoping to take full advantage of local preferential policies and establish and improve the group's raw material production and supply capacity at a relatively optimal cost, and establish a reliable strategic cooperation and partner relationship for the group's core products in China. Currently, it is actively communicating with the local government and interests.
Kunshengtai Medicine-B (02511): It has decided to establish a production raw material operation main base in Nandagang Industrial Park of Bohai New District, Cangzhou, Hebei Province.
Junshengtai pharmaceutical-B (02511) announced that after consultation with relevant regional government departments, the group has decided to establish a production raw material operation main base in Nandagang industrial park, Bohai New Area, Cangzhou, Hebei Province. Through business expansion plans, the group expects to fully utilize local preferential policies and establish and enhance the group's raw material production and supply capabilities at a relatively lower cost, in order to establish reliable strategic cooperation and partnership for the group's core products in China. The company believes that the above business expansion plan is in line with the overall interests of the company and its shareholders.
Express News | HighTide Therapeutics Inc - Actively Communicating With Local Authorities and Stakeholders on Business Expansion Plan
Statistics on unusual proportion of SmartHK Connect on June 28th.
Abnormal statistical proportion of ChiNext Stock Connect on June 27th, 2024.
Patient enrollment has been completed for the Phase III clinical trial of HTD1801 for the treatment of type II diabetes by KunShengTai Pharmaceutical-B (02511.HK).
On June 27th, Healthcare International-B (02511.HK) announced that the company's self-developed intestinal and hepatic anti-inflammatory and metabolic regulator HTD1801 (berberine dihydrochloride) has completed patient enrollment for 2 Phase III clinical registration trials for type 2 diabetes (T2DM) patients. The two Phase III registration trials are as follows: HTD1801.PCT105: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-1) evaluating the efficacy and safety of HTD1801 in type 2 diabetes patients with poor blood glucose control after dietary and exercise interventions.
Statistics of abnormal proportion of Stock Connect of China Tong in Zhixun|June 27.
Abnormal statistics of Smart Hong Kong Stock Connect Proportion | 26th June 2024
HK stock market anomaly | Kinsmed Biopharmaceuticals-B (02511) opened higher by nearly 6% today, after a sharp drop of over 60% during yesterday's trading, the company confirmed that its business operations are normal.
Kun Sheng Tai Medicine-B (02511) plummeted by more than 60% during the trading session yesterday, and opened high by nearly 6% this morning. As of the time of writing, it has risen by 5.92% to HKD 1.61, with a turnover of HKD 2.8811 million.
Here's Why We're Watching HighTide Therapeutics' (HKG:2511) Cash Burn Situation
Kingsunite Pharmaceutical-B (02511): Unusual fluctuations in stock price for unknown reasons.
Kun Sheng Tai Medicine-B (02511) issued an announcement that the price of the company's shares has recently experienced unusual fluctuations.
Express News | HighTide Therapeutics Inc - Not Aware of Any Reasons for Recent Fluctuation in Price of Shares
Express News | HighTide Therapeutics Inc - Noted Recent UnUsUaL Fluctuation in Price of Shares
HK stocks fluctuate | Kin Shing Tai Medicine-B (02511) fell more than 21%, hitting a new low again and falling more than 70% in the first half of the year since listing.
Junshengtai Pharmaceutical-B (02511) fell more than 21%, reaching a new low of HK$2.78 since its listing. The stock has fallen more than 76% in the six months since it went public. As of press time, it fell 20.61%, reporting HK$2.85, with a turnover of HK$11.6294 million.
Express News | HighTide Therapeutics Presents Analyses of Phase 2a Mash Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
HIGHTIDE-B: 2023 ANNUAL REPORT
Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) once rose more than 42% and previously announced the completion of the phase IIb clinical trial of HTD1801 to enroll patients
Junshengtai Pharmaceutical-B (02511) once rose by more than 42%. As of press release, it rose 23.49% to HK$5.31, with a turnover of HK$12.3888 million.
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
Junshengtai Pharmaceutical-B (02511.HK): HTD1801 clinical trial to treat metabolic steatohepatitis (MASH) phase IIb completed patient enrollment
Gelonghui, April 3 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberberis), developed independently by the company, has enrolled patients. The trial targets patients with metabolic fatty hepatosis (MASH for short) with type 2 diabetes (T2DM) or pre-diabetes. This trial (Centricity study) is a randomized, double-blind, placebo-controlled global multicenter phase IIb clinical trial aimed at evaluating HTD1801 in
Junshengtai Pharmaceutical-B (02511) released annual results, R&D costs of 312 million yuan, an increase of 70.6% over the previous year
Junshengtai Pharmaceutical-B (02511) announced 2023 results, other revenue and revenue of 34.2 million yuan (people...
Analysis
Price Target
No Data
